Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: Guideline update

Medical Journal of Australia

Volumn 200, Issue 5, 2014, Pages 267-270

  O'Brien, Daniel P ^a,b   Jenkin, Grant ^c   Buntine, John ^d   Steffen, Christina M ^e   McDonald, Anthony ^a   Horne, Simon ^f   Deborah Friedman, N ^a   Athan, Eugene ^a   Hughes, Andrew ^a   Callan, Peter P ^g   Johnson, Paul D R ^h,i  

^a BARWON HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Southern Health   (Australia)

^d Cornell Specialist Centre ^*  (Australia)

^e CAIRNS BASE HOSPITAL   (Australia)

^f Point Lonsdale Medical Group   (Australia)

^g ST JOHN OF GOD HOSPITAL   (Australia)

^h AUSTIN HEALTH   (Australia)

ⁱ VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CIPROFLOXACIN; CLARITHROMYCIN; MOXIFLOXACIN; PREDNISOLONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; AUSTRALIA; BURULI ULCER; CLINICAL PRACTICE; DISEASE TRANSMISSION; DRUG DOSE REDUCTION; FINE NEEDLE ASPIRATION BIOPSY; HEALTH CARE COST; HUMAN; HYPERTHERMIC THERAPY; MORBIDITY; PARADOXICAL DRUG REACTION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; WORLD HEALTH ORGANIZATION; DEBRIDEMENT; DRUG COMBINATION; HEAT; MYCOBACTERIUM ULCERANS;

ANTI-BACTERIAL AGENTS; AUSTRALIA; BURULI ULCER; DEBRIDEMENT; DRUG THERAPY, COMBINATION; HOT TEMPERATURE; HUMANS; MYCOBACTERIUM ULCERANS; PRACTICE GUIDELINES AS TOPIC; RIFAMPIN; STREPTOMYCIN;

EID: 84899895430     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja13.11331     Document Type: Article

References (43)

1. Johnson PD, Stinear T, Small PL, et al. Buruli ulcer (M. ulceransinfection): new insights, new hope for disease control. PLOS Med 2005; 2: e108.
2. George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999; 283: 854-857.
3. Boyd SC, Athan E, Friedman ND, et al. Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population. Med J Aust 2012; 196: 341-344.
4. Jenkin GA, Smith M, Fairley M, Johnson PD. Acute, oedematousMycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust 2002; 176: 180-181.
5. Steffen CM, Smith M, McBride WJ. Mycobacterium ulcerans infection in North Queensland: the 'Daintree ulcer'. ANZ J Surg 2010; 80: 732-736.
6. Francis G, Whitby M, Woods M. Mycobacterium ulcerans infection: a rediscovered focus in the Capricorn Coast region of central Queensland. Med J Aust 2006; 185: 179-180.
7. Quinn JV, Crotty JM. Mycobacterium ulcerans infections in the Northern Territory. Med J Aust 1963; 2: 317-319.
8. Johnson PD, Hayman JA, Quek TY, et al. Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulceransinfection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 2007; 186: 64-68.
9. O'Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007; 186: 58-61.
10. Bentoucha A, Robert J, Dega H, et al. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2001; 45: 3109-3112.
11. Ji B, Chauffour A, Robert J, et al. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2007; 51: 3737-3739.
12. Ji B, Lefrançois S, Robert J, et al. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother2006; 50: 1921-1926.
13. Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother2005; 49: 3182-3186.
14. Gordon CL, Buntine JA, Hayman JA, et al. All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLOS Negl Trop Dis 2010; 4: e770.
15. O'Brien DP, McDonald A, Callan P, et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment ofMycobacterium ulcerans: an observational cohort study. PLOS Negl Trop Dis 2012; 6: e1473.
16. Friedman ND, Athan E, Hughes AJ, et al. Mycobacterium ulceransdisease: experience with primary oral medical therapy in an Australian cohort. PLOS Negl Trop Dis 2013; 7: e2315.
17. Ross BC, Marino L, Oppedisano F, et al. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol1997; 35: 1696-1700.
18. Yeboah-Manu D, Danso E, Ampah K, et al. Isolation of Mycobacterium ulcerans from swab and fine-needle-aspiration specimens. J Clin Microbiol2011; 49: 1997-1999.
19. Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375: 664-672.
20. Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007; 51: 4029-4035.
21. Sarfo FS, Phillips R, Asiedu K, et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulceransdisease. Antimicrob Agents Chemother 2010; 54: 3678-3685.
22. Chauty A, Ardant MF, Marsollier L, et al. Oral treatment forMycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 2011; 52: 94-96.
23. World Health Organization. Treatment of Mycobacterium ulceransdisease (Buruli ulcer): guidance for health workers. Geneva: WHO, 2012.
24. Thangaraj HS, Adjei O, Allen BW, et al. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates ofMycobacterium ulcerans. J Antimicrob Chemother 2000; 45: 231-233.
25. Saito H, Ishii N. Antibacterial activities of new fluoroquinolones againstMycobacterium ulcerans. J Antimicrob Chemother 2001; 47 Suppl 1: 30.
26. O'Brien DP, Athan E, Hughes A, Johnson PD. Successful treatment ofMycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report. J Med Case Rep 2008; 2: 123.
27. Yoshida K, Yabe K, Nishida S, et al. Pharmacokinetic disposition and arthropathic potential of oral ofloxacin in dogs. J Vet Pharmacol Ther 1998; 21: 128-132.
28. Zimbabwe, Bangladesh, South Africa (Zimbasa) Dysentery Study Group. Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J 2002; 21: 1136-1141.
29. Simpson C, O'Brien DP, McDonald A, Callan P. Mycobacterium ulceransinfection: evolution in clinical management. ANZ J Surg 2013; 83: 523-526.
30. O'Brien DP, Walton A, Hughes AJ, et al. Risk factors for recurrentMycobacterium ulcerans disease after exclusive surgical treatment in an Australian cohort. Med J Aust 2013; 198: 436-439.
31. Nienhuis WA, Stienstra Y, Abass KM, et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 2012; 54: 519-526.
32. O'Brien DP, Robson M, Friedman ND, et al. Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis 2013; 13: 416.
33. Ruf MT, Chauty A, Adeye A, et al. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLOS Negl Trop Dis 2011; 5: e1252.
34. O'Brien DP, Robson ME, Callan PP, McDonald AH. "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 2009; 191: 564-566.
35. Friedman ND, McDonald AH, Robson ME, O'Brien DP. Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans. PLOS Negl Trop Dis 2012; 6: e1767.
36. Trevillyan JM, Johnson PD. Steroids control paradoxical worsening ofMycobacterium ulcerans infection following initiation of antibiotic therapy. Med J Aust 2013; 198: 443-444.
37. Junghanss T, Um Boock A, Vogel M, et al. Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLOS Negl Trop Dis 2009; 3: e380.
38. Johnson PD, Azuolas J, Lavender CJ, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007; 13: 1653-1660.
39. Quek TY, Henry MJ, Pasco JA, et al. Mycobacterium ulcerans infection: factors influencing diagnostic delay. Med J Aust 2007; 187: 561-563.
40. Johnson PD, Lavender CJ. Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia. Emerg Infect Dis 2009; 15: 614-615.
41. Fyfe JA, Lavender CJ, Handasyde KA, et al. A major role for mammals in the ecology of Mycobacterium ulcerans. PLOS Negl Trop Dis 2010; 4: e791.
42. Pouillot R, Matias G, Wondje CM, et al. Risk factors for buruli ulcer: a case control study in Cameroon. PLOS Negl Trop Dis 2007; 1: e101.
43. Landier J, Boisier P, Fotso Piam F, et al. Adequate wound care and use of bed nets as protective factors against Buruli ulcer: results from a case control study in Cameroon. PLOS Negl Trop Dis 2011; 5: e1392.